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Introduction
The adenosine receptor (AR) family of G protein-coupled receptors (GPCRs) consists of four subtypes, the A 1 AR, A 2A AR, A 2B AR, and A 3 AR. The A 1 AR is widely distributed within the body with high levels found in the central nervous system and peripheral organs (Palmer and Stiles, 1995; Fredholm et al., 2001; Yaar et al., 2004) . Preferentially coupled to G i/o proteins, A 1 AR stimulation can reduce cardiac and renal ischemia reperfusion injury, atrial fibrillation and neuropathic pain (Fredholm et al., 2001) . Further, A 1 AR antagonists may be beneficial as potassium-saving diuretics (Jacobson and Gao, 2006; Müller and Jacobson, 2011) and cognition enhancers (Hess, 2001) . Consequently, the A 1 AR is an attractive therapeutic target and a detailed understanding of ligand binding and function is imperative for this clinically relevant target.
Recently, structures of the human A 2A AR co-crystallized with various agonists and antagonists have been solved, providing deep insight into the orthosteric ligand binding region (Jaakola et al., 2008; Lebon et al., 2011; Xu et al., 2011; Doré et al., 2011; Congreve et al., 2012; Hino et al., 2012; Liu et al., 2012; Lebon et al., 2015) . These crystal structures suggest that both helical transmembrane (TM) domains and extracellular loops (ECLs) contribute to the geography of the orthosteric pocket.
In particular, an integral role for the helical region of ECL2 was highlighted, with Phe168 and Glu169 in this loop forming a π -stacking interaction and hydrogen bonding, respectively, with both antagonist and agonists.
Previous homology modeling and mutagenesis studies suggested that the A 1 AR orthosteric binding pocket is located within the TM bundle, with key roles attributed to residues L88 3.33 , T91 3.36 , Q92 3.37 and T277 7.42 (Townsend-Nicholson and Schofield, 1994; Rivkees et al., 1999) . However ECL2, a region with high sequence variability across the adenosine receptor subtypes, has also been implicated in A 1 AR orthosteric agonist and antagonist pharmacology (Olah et al., 1994) . Similarly, an emerging picture of the contribution of ECL2 in orthosteric ligand recognition, and even the This article has not been copyedited and formatted. The final version may differ from this version.
Molecular Pharmacology Fast Forward. Published on as DOI: 10.1124 at ASPET Journals on October 26, 2016 molpharm.aspetjournals.org Downloaded from ability of GPCRs to transition between multiple functional states, has been more broadly suggested for other AR subtypes and family A GPCRs, including the A 2A AR, A 3 AR, cannabinoid receptor 1, M 2 and M 3 muscarinic acetylcholine receptors, rhodopsin, β-adrenoceptors, dopamine receptors, chemokine receptor 4 and V 1a vasopressin receptor (Olah et al., 1994; Kim et al., 1996; Howl and Wheatley, 1996; Gao et al., 2002; Shi and Javitch, 2004; Avlani et al., 2007; Scarselli et al., 2007; Gregory et al., 2010; Sabbadin et al., 2015) . In particular, ECL2 residues in the area adjacent to the highly conserved disulfide-bonding cysteine appear to play a key role in agonist binding and function at family A GPCRs (Wheatley et al., 2012) . At the human A 2A AR, glutamate residues in ECL2 have also been suggested to be involved in orthosteric ligand recognition (Kim et al., 1996) .
Furthermore, a recent seminal study using unbiased long time-scale molecular dynamics (MD) simulations highlighted a role for ECL2 in entry and egress of β -adrenoceptor orthosteric ligands from the binding pocket. Interestingly, in that study, the trajectory of ligands into the orthosteric pocket involved a metastable state in an extracellular vestibule, delineated by ECL2 and ECL3, prior to entry into the binding pocket within the helical bundle (Dror et al., 2011) . It is possible that this paradigm extends to other receptors, and that the residence time a ligand spends in this metastable state prior to engaging the canonical orthosteric site may have implications for receptor activation dynamics and potential allosteric targeting.
Therefore, the aim of the current study was to establish the role of the A 1 AR-ECL2 in orthosteric ligand binding and function using a combination of mutagenesis, quantitative analytical pharmacology and molecular modeling. Complete alanine scanning of ECL2 residues was performed and the effects on orthosteric ligand affinity and efficacy quantified using radioligand binding and cAMP accumulation assays. Interpretation of mutagenesis data was facilitated by ligand docking into A 1 AR homology models based on agonist and antagonist bound A 2A AR crystal structures followed by MD simulations. Ligand docking poses were evaluated by identification and mutational validation of novel ligand-receptor interactions within the A 1 AR. Collectively, our were then sub-cloned into the Gateway destination vector pEF5/FRT/V5-DEST using the LR clonase enzyme mix (Invitrogen).
Transfections and Cell Culture
DNA constructs in the pEF5/FRT/V5-DEST destination vector were stably transfected into Flp-In™-CHO cell line as described previously (May et al., 2007) . Briefly, Flp-In™-CHO cells were transfected in serum and antibiotic-free DMEM with 0.7 μ g of pEF5/FRT/V5-DEST vector containing the wild-type (WT) or mutant 3xHA-A 1 AR constructs and 7 μ g of pOG44 vector using Lipofectamine 2000 (30 μL/25 cm 2 flask). Flp-In™-CHO cells stably expressing human A 1 AR (untagged) were generated previously (Valant et al., 2014) . Cells were selected and maintained in DMEM containing 10% FBS and 600 μ g/mL hygromycin B in a humidified environment at 37°C in 5% CO 2 .
Radioligand binding assay
Cells were seeded at 40,000 cells/well into a transparent 96-well plate and incubated in a humidified environment at 37 o C in 5% CO 2 . After 8 h, cells were washed with serum free DMEM and maintained in serum free DMEM for approximately 18 h at 37°C in 5% CO 2 before assaying. pyrimidin-4yl)amino]cyclohexanol), a selective A 1 AR antagonist (Kalk et al., 2007) . Assays were terminated This article has not been copyedited and formatted. The final version may differ from this version. 
cAMP accumulation assay
Inhibition of forskolin-stimulated cAMP accumulation assays were performed as described previously (Baltos et al., 2016) . Briefly, cells were seeded at 20,000 cells/well into a transparent 96well plate and incubated in a humidified incubator at 37 o C in 5% CO 2 overnight. Media was then 
Data Analysis
All data were analysed using GraphPad Prism 6.03 (GraphPad Software, San Diego, CA). Relative receptor expression (B max ) and [ 3 H]DPCPX equilibrium dissociation constants (K A ) were determined from saturation binding assays using the following equation: where Y is radioligand binding, B max is the total receptor density, [A] is the radioligand concentration, K D is the equilibrium dissociation constant of the radioligand, and NS is nonspecific radioligand binding.
[ 3 H]DPCPX competition binding curves were fitted to a one-site inhibitory mass action equation:
where Y is the specific binding and IC 50 is the concentration of ligand that displaces 50% NECA concentration-response curves were fitted to the following form of the operational model of agonism (Black and Leff, 1983) :
where E m is the maximal system response, A is the agonist concentration, τ is an index of coupling efficiency (efficacy) of the agonist and is defined as R T /K E (where R T is the total concentration of receptors, i.e., B max , and K E is the concentration of agonist-receptor complex that yields half the E m ), and n is the slope of the transducer function that links occupancy to response; the latter parameter was constrained to be shared across all datasets, as an extra- from saturation binding were used to normalize the τ values derived from the operational model analysis (Gregory et al., 2010) ; these values are reported as "corrected τ values", τ c .
Statistical analysis was performed using a Student's t-test or a one-way ANOVA analysis of variance with a Dunnett's post-test as indicated was used to determine statistical differences (P < 0.05) where appropriate.
Molecular Modeling
Homology Modeling of the A 1 AR
The human A 1 AR and A 2A AR share approximately 40% sequence identity and therefore A 2A R crystal structures are acceptable templates for A 1 AR homology models to gain a better understanding of ligand interactions at the A 1 AR. The sequence of the human A 1 AR was retrieved from the Swiss-Prot database. ClustalX software (Thompson et al., 1997) was used to align the A 1 AR sequence with the crystal structures of the antagonist and agonist-bound human A 2A AR (PDB ID: 3EML (Jaakola et al., 2008) and 3QAK for the inactive and partially active states, respectively). 3D structures of the A 1 AR were constructed with MODELLER v9.12 (Eswar et al., 2007) . The conserved disulfide bond between residue C80 3.25 at the top of TM3 and C169 ECL2 and the ECL3 intra-loop disulfide bond between C260 ECL3 and C263 ECL3 present in the template structure were built and maintained as a constraint for geometric optimization. The best structure was selected based on the Modeller DOPE (Discrete Optimized Protein Energy) assessment score and visual inspection. Structures obtained were optimized using the Duan force field (Duan et al., 2003) .
Docking of adenosine receptor ligands
Docking of DPCPX and NECA was performed using ICM version 3.8.0 (Molsoft L.L.C., La Jolla, CA). Potential binding sites were predicted using the ICM Pocket Finder algorithm Abagyan and Kufareva, 2009 Å x 30 Å (the region in which 0.5 Å grid energy maps were generated), this size is large enough to encompass the potential orthosteric binding pocket and the extracellular region of the receptor.
Docking thoroughness, representing the length of the docking simulation, used default settings.
Ligand binding modes were ranked according to ICM score, which is inversely proportional to the number of favorable intermolecular interactions between the docked ligand and the receptor. The docking of each ligand was repeated five times and the conformation with the lowest ICM score selected for subsequent MD simulations.
Molecular Dynamics Simulations
MD simulations of the final complex were carried out with the NAMD2.10 (Phillips et al., 2005) package using the 3-site rigid water TIP3P model, CHARMM27 (MacKerell et al., 1998; Mackerell et al., 2004) , and CGenFF (Vanommeslaeghe et al., 2010; Yu et al., 2012) v.3.0.1 force fields as described previously (Aksimentiev et al., 2012; Shonberg et al., 2013) . The particle mesh Ewald (PME) (Essmann et al., 1995) method was used to evaluate electrostatic interactions. Each system contains an A 1 AR receptor, the ligand, a lipid bilayer containing ~220 1-palmitoyl-2-oleoyl-snglycero-3-phosphocholine (POPC) molecules generated using the membrane plugin of the VMD software (v1.9.2) (Humphrey et al., 1996) , and ~15800 water molecules. Sodium and chloride ions were added to neutralize the system, with extra NaCl added to reach a final concentration of 150 mM (~35 sodium ions, ~48 chloride ions). Two energy minimization and equilibration periods were performed prior to the MD production run. The first involved energy minimization and a 15 ns equilibration of lipids tails. The second involved energy minimization and a 5 ns equilibration of the whole system, with 10 kcal mol −1 Å −2 harmonic-position restraints applied to all heavy atoms of the protein and ligands. Subsequently, the production run of the final unconstrained system was performed for 40 ns using a 2 fs integration time step in the NPT ensemble (310K, 1 bar).
Coordinates were written to the output trajectory file every 10 ps. VMD v1.9.2 was used for the visualization and analysis of the residue-ligand contacts through the course of each simulation using in-house scripts. The percentage total MD time that residues were involved in hydrogen bonding This article has not been copyedited and formatted. The final version may differ from this version. and/or found within 3.5 Å of DPCPX or NECA heavy atoms was quantified for each MD simulation. All figures were generated using PYMOL.
Results
The 3xHA-A 1 AR has comparable pharmacology to the human A 1 AR
In this study, the role of ECL2 residues on agonist binding and function was investigated using human A 1 AR constructs with an N-terminal triple HA epitope tag (3xHA-A 1 AR). Previous studies on other GPCRs have shown that the addition of an N-terminal HA-tag generally does not interfere with receptor pharmacology (Sromek and Harden, 1998; Leach et al., 2011; Schiedel et al., 2011) .
To ensure the pharmacology of the 3xHA-A 1 AR was equivalent to the untagged human A 1 AR, we compared agonist and antagonist affinity estimated between the two constructs. In homologous competition binding studies, the N-terminal 3xHA tag significantly reduced receptor expression (B max ) (A 1 AR B max = 5343 ± 234.6, 3xHA-A 1 AR B max = 2022 ± 155; n = 3 -6; P < 0.05, Student's t-test), however, DPCPX affinity was unaffected (A 1 AR pK I = 8.84 ± 0.08, 3xHA-A 1 AR pK I = 8.96 ± 0.11; n = 3 -6; P > 0.05, Student's t-test). In heterologous competition binding studies, NECA affinity was also unaffected (A 1 AR pK I = 6.48 ± 0.01, 3xHA-A 1 AR pK I = 6.59 ± 0.04; n = 3 -44; P > 0.05, Student's t-test). Therefore despite having decreased cell surface expression, the N-terminal 3xHA epitope tagged human A 1 AR has equivalent affinity with the orthosteric ligands to the untagged human A 1 AR.
Cell surface expression of human 3xHA-A 1 AR ECL2 alanine mutants
The generalized numbering scheme proposed by Ballesteros and Weinstein was used for transmembrane residues (Ballesteros and Weinstein, 1995) . Alanine scanning mutations were performed within ECL2 of the A 1 AR, with the exception of C169 ECL2 . Residues C80 3.25 and C169 ECL2 are predicted to form a conserved disulphide bond, and alanine substitution of C169 ECL2 has previously been shown to abolish [ 3 H]DPCPX specific binding (Scholl and Wells, 2000;  This article has not been copyedited and formatted. The final version may differ from this version. Martinelli and Tuccinardi, 2008) . Single alanine mutations were performed, with the exception of S150 ECL2 A + V151 ECL2 A (SV150 ECL2 AA) and M162 ECL2 A + G163 ECL2 A + E164 ECL2 A (MGE162 ECL2 AAA), for which the double and triple mutations were similarly expressed ( Fig. 1A) .
Cell surface expression of each mutant 3xHA-A 1 AR stably expressed in Flp-In™-CHO cells was determined from whole cell [ 3 H]DPCPX saturation binding (Fig. 1B, Fig. 2A Table 2 ).
ECL2 alanine substitutions influence A 1 AR orthosteric ligand affinity
The affinity of the orthosteric antagonist [ 3 H]DPCPX and orthosteric agonist NECA was determined from whole cell saturation and competition binding assays, respectively ( Fig. 2A, Fig.   2B , Table 1 ). When compared to the WT 3xHA-A 1 AR, alanine substitution of multiple residues (N159 ECL2 , S161 ECL2 , I167 ECL2 , E172 ECL2 , I175 ECL2 and M177 ECL2 ) located in the middle to end of ECL2, significantly decreased [ 3 H]DPCPX affinity (pK D ) (Fig. 3A) . The same residues had a similar or greater effect on NECA affinity (pK I ) ( Fig. 3B ), suggesting that these ECL2 residues facilitate, through direct or indirect interactions, the binding of [ 3 H]DPCPX and NECA at the This article has not been copyedited and formatted. The final version may differ from this version. A 1 AR. Three additional ECL2 mutations, W146 ECL2 A, L149 ECL2 A and E170 ECL2 A, had a modest effect on NECA affinity (Fig. 3B, Table1 ).
ECL2 alanine substitutions influence A 1 AR orthosteric agonist efficacy
To investigate the influence of ECL2 on A 1 AR agonist efficacy, NECA-mediated inhibition of forskolin-stimulated cAMP accumulation was quantified in WT and mutant 3xHA-A 1 AR Flp-In™-CHO cell lines (Fig. 2C) . The NECA-mediated inhibition of cAMP accumulation was comparable in the absence and presence of adenosine deaminase, suggesting minimal influence of endogenous adenosine (unpublished results). Furthermore, we have recently demonstrated that the Flp-In™-CHO cell line stably expressing the wild-type A 1 AR was not associated with measureable constitutive activity (Vecchio et al., 2016) . Similarly, comparison of the cAMP accumulation stimulated by forskolin (3 μM) found no evidence for A 1 AR constitutive activity in Flp-In™-CHO cells stably expressing mutant A 1 ARs (unpublished results). An operational measure of efficacy (logτ), corrected for relative receptor expression levels, was used to quantify efficacy changes at mutant 3xHA-A 1 ARs compared to the WT 3xHA-A 1 AR. Negligible NECA-mediated inhibition of cAMP accumulation was observed in the Flp-In™-CHO cell line expressing the 3xHA-A 1 AR(F171 ECL2 A) (data not shown). Interestingly, the cluster of 7 residues at the C-terminal end of the ECL2 that significantly reduced NECA affinity had no impact on NECA efficacy (logτ c ).
NECA efficacy was significantly reduced, however, at 5 of the mutant 3xHA-A 1 ARs (Fig. 4 , Table   1 ). Of note, NECA efficacy was significantly reduced upon alanine substitution of N148 ECL2 , E153 ECL2 , R154 ECL2 and W156 ECL2 ; mutations that had no significant effect on NECA affinity. In contrast to the effect of L149 ECL2 A in improving NECA affinity, the same mutation decreased NECA efficacy.
Ligand Docking and Molecular Dynamics Simulations
This article has not been copyedited and formatted. The final version may differ from this version. (Jaakola et al., 2008; Xu et al., 2011) . Ligand docking and MD simulations were performed using our inactive and active-like A 1 AR homology models to assist with the interpretation of mutagenesis findings. The ICM PocketFinder algorithm identified three potential binding pockets within our A 1 AR homology models. DPCPX and NECA were docked into the pocket located within the TM bundle, however the size of docking box was adjusted to be large enough to encompass the extracellular region of the receptor. Docking simulations of DPCPX resulted in a single cluster within the TM bundle, where DPCPX formed a π -stacking interaction with F171 ECL2 (Fig. 5A ); this key interaction was maintained during a 40 ns MD simulation (Table 2) . Furthermore, the key residue, N254 6.55 , involved in hydrogen bonding interactions in both antagonist and agonist bound A 2A AR crystal structures, formed a hydrogen bond with DPCPX during the MD simulation (Table 2) . E172 ECL2 , another key residue involved in the formation of the DPCPX binding pocket, that is, found within 3.5 Å of DPCPX during the MD simulation, also decreased [ 3 H]DPCPX affinity when mutated to alanine ( Table 2 ). The root-meansquare-deviation of DPCPX compared to its final pose was calculated. Over the course of the simulation, DPCPX remained relatively stable after 12 ns (Supplemental Fig. 2) .
Interestingly, molecular docking of NECA revealed two main clusters amongst the top 40 docking poses, one within the TM bundle ('Site 1') and the other within the extracellular region ('Site 2') ( Fig. 5B ). Similar findings were also observed when we repeated the molecular docking using the endogenous agonist adenosine instead of NECA (Supplemental Fig 3) . The NECA poses found within the TM bundle (Site 1) were located within the predicted A 1 AR orthosteric agonist site.
Within Site 1, poses could be further divided into two sub-clusters. One sub-cluster had a similar This article has not been copyedited and formatted. The final version may differ from this version. orientation of the adenine ring to that found within the NECA bound A 2A AR crystal structure and was relatively stable during our 40 ns MD simulation (Supplemental Fig. 2 ). During this simulation, NECA predominantly formed hydrogen bond interactions with the residues T91 3.36 , N254 6.55 and T277 7.42 . The only ECL2 residue located within 3.5 Å of NECA during this MD simulation was F171 ECL2 (Table 2 ). The alternative cluster of NECA Site 1 poses was not considered for MD simulations, as the adenine ring was inverted relative to the position of NECA bound within the A 2A AR crystal structure.
NECA poses that docked within the A 1 AR extracellular region (Site 2) formed hydrogen bonds with the three extracellular loops and residues at the top of TM6 and TM7. A 40 ns MD simulation was performed on the highest ranked (lowest ICM score) pose within the extracellular vestibule.
Within this MD simulation, NECA was relatively stable and formed hydrogen bonds with a number of residues including E170 ECL2 , E172 ECL2 , N254 6.55 , K265 ECL3 , P266 ECL3 and T270 7.35 (Table 2; Supplemental Fig. 2 ). ECL2 residues located within 3.5 Å of NECA during this MD simulation were E170 ECL2 , F171 ECL2 , E172 ECL2 and M177 ECL2 (Table 2 ). These findings are consistent with mutagenesis data that suggest each of these residues are involved in the binding of NECA to the A 1 AR (Table 1) .
A main pose of each ligand, which formed key interactions as determined by the interaction frequency analysis of the MD trajectory, was obtained from each 40 ns MD simulation (Fig. 6, Fig.   7 , Data Supplement 1-3). The purine rings for the DPCPX and NECA (Site 1) poses overlap, stabilized by a H-bond with N254 6.55 and π -stacking interactions with F171 ECL2 (Supplemental Fig.   4 ). Residues within the extracellular vestibule, top of TM6 (L250 6.51 , L253 6.54 and T257 6.58 ) and E172 ECL2 surrounded the DPCPX cyclopentyl ring, whereas the NECA ribose moiety made contacts with residues deeper within the TM bundle (V87 3.32 , L88 3.33 , Q92 3.37 , M180 5.40 , and W247 6.48 ).
NECA was further anchored by a predicted hydrogen-bond with T91 3.36 (Fig. 7A, Fig. 7B ).
This article has not been copyedited and formatted. The final version may differ from this version. Therefore, the residues predicted to form the NECA Site 1 binding pocket involve conserved residues between the A 1 AR and A 2A AR, V87 3.32 , L88 3.33 , T91 3.36 , Q92 3.37 , M180 5.40 , W247 6.48 , L250 6.51 and N254 6.55 . These residues are predicted to be involved in conformational rearrangements of TM3, 5, 6 and 7 upon receptor activation and facilitate the binding of orthosteric agonists (Supplemental Fig. 4) Lebon et al., 2011) . The main NECA binding pose within Site 2 was predicted to be stabilized by H-bond interactions between the adenine ring and E170 ECL2 , E172 ECL2 , S267 ECL3 , and T270 7.35 as well as a H-bond between the 2´-OH group of ribose ring and K265 ECL3 (Fig. 7C, Fig. 7D ). The NECA Site 2 binding pocket was also closely packed by F171 ECL2 , M177 ECL2 and T257 6.58 side chains. Interestingly, the NECA (Site 2) and DPCPX poses were not topographically distinct and instead predicted to partially overlap.
Alanine substitution of predicted binding pocket residues from molecular modeling impact NECA affinity and/or efficacy
Results from the NECA Site 1 MD simulations found T91 3.36 , F171 ECL2 and W247 6.48 located within 3.5 Å of NECA heavy atoms for at least 60% of the total MD simulation time. Whereas the NECA Site 2 MD simulation found E172 ECL2 , K265 ECL3 and T270 7.35 located within 3.5 Å of NECA heavy atoms for at least 60% of the total MD simulation time. The corresponding conserved residues T91 3.36 , F171 ECL2 and E172 ECL2 directly interact with NECA within the A 2A AR crystal structure.
Furthermore, the involvement of the TM residue T91 3.36 on A 1 AR agonist binding has been confirmed previously through mutagenesis studies (Rivkees et al., 1999) . The conserved tryptophan at position 6.48 has been suggested to be involved in the activation process of GPCRs (Shi et al., 2002; Kobilka et al., 2007; Stoddart et al., 2014) . Given the known role of T91 3.36 and W247 6.48 in A 1 AR orthosteric binding, these residues were not investigated further in the current study.
However, the influence of the predicted NECA Site 2 residues, K265 ECL3 and T270 pharmacology. Consistent with DPCPX binding within the TM bundle, neither mutation significantly influenced receptor expression ( Fig. 8A) or DPCPX affinity (Fig. 8B) . In contrast, alanine substitution of T270 7.35 caused a significant decrease in NECA affinity (Fig. 8C ).
Furthermore, both mutations significantly decreased NECA efficacy (Fig. 8D) . These data suggest that residues in the extracellular region of the A 1 AR play an important role in both agonist binding and function.
This article has not been copyedited and formatted. The final version may differ from this version. 
Discussion
The A 1 AR represents a potential therapeutic target for a number of conditions. A detailed understanding of the structure-function relationships at the A 1 AR can facilitate the rational design of more potent and selective A 1 AR ligands. Since a high resolution structure of the A 1 AR bound to different classes of ligand is not yet available, less direct methods such as site-directed mutagenesis and molecular modeling that can probe the structure-function properties underlying A 1 AR orthosteric ligands remain extremely valuable. Given that ECL2 has been suggested to have a critical role in the binding and function of orthosteric ligands at a range of GPCRs (Wheatley et al., 2012) , we performed alanine scanning mutagenesis of this region combined with molecular modeling to identify the role of this domain on orthosteric ligand pharmacology. Moreover, key residues predicted from MD to be involved orthosteric agonist function were mutated, and the effects of the mutations validated the importance of these residues. Our A 1 AR-ECL2 mutagenesis data are in good agreement with the binding modes of DPCPX and NECA from molecular modeling, identifying a key role for ECL2 in A 1 AR orthosteric ligand binding and function.
However, our data also suggest that the orthosteric agonist, NECA, recognizes a binding site in an extracellular vestibule that may represent a transition pose prior to entry into the canonical orthosteric site. This vestibular region may represent part of an allosteric binding site for A 1 AR modulators, and this is explored in greater detail in our accompanying article.
Previous A 1 AR site-directed mutagenesis studies have predominantly focused on TM domains, with residues in TM 1, 2, 3, 4, 5, and 7 implicated in the binding of orthosteric agonists and antagonists (Olah et al., 1994; Townsend-Nicholson and Schofield, 1994; Barbhaiya et al., 1996; Rivkees et al., 1999; Fredholm et al., 2001) . Until now, the involvement of ECL2 on orthosteric ligand binding and function has not been systematically investigated at the A 1 AR. However, a critical role for this domain on orthosteric pharmacology has been identified from mutagenesis studies on other GPCRs, such as the A 3 AR, dopamine D 2 receptor, M 2 and M 3 muscarinic receptors, V 1a vasopressin receptor This article has not been copyedited and formatted. The final version may differ from this version. and glucagon-like peptide-1 receptor (Howl and Wheatley, 1996; Gao et al., 2002; Shi and Javitch, 2004; Duong et al., 2005; Avlani et al., 2007; Scarselli et al., 2007; Koole et al., 2012) . It is suggested that orthosteric ligand binding to an unoccupied GPCR, which has a more exposed ECL2, can induce a conformational change, causing ECL2 to close over the entrance to the binding crevice and thereby stabilize the ligand within the orthosteric pocket (Banères et al., 2005; Unal et al., 2010) . Supporting this notion, ECL2 contributes to the orthosteric pocket in A 2A AR crystal structures. The short helical domain within the A 2A AR-ECL2 is oriented towards the TM core region and interacts directly with agonists and antagonists in the orthosteric site (Jaakola et al., 2008; Lebon et al., 2011; Xu et al., 2011; Doré et al., 2011; Congreve et al., 2012; Hino et al., 2012; Liu et al., 2012; Lebon et al., 2015) . Molecular modeling performed within the current study, also suggests the short helical domain within the A 1 AR-ECL2 forms the upper region of the principal orthosteric pocket. The main pose from MD simulations performed on DPCPX and NECA docked within the TM bundle found two ECL2 residues, F171 and E172, located within 3.5 Å of the orthosteric ligand (Fig. 6, Fig. 7) . Supporting a role of these residues in DPCPX binding at the A 1 AR, a decrease in [ 3 H]DPCPX and NECA affinity was observed for the E172 ECL2 A and no [ 3 H]DPCPX binding was observed at the F171 ECL2 A mutation.
Docking of DPCPX and NECA into homology models based on inactive and active-like A 2A AR crystal structures, respectively, revealed overlapping binding poses, with NECA (bound to Site 1) making additional contacts with residues deeper within the TM bundle than DPCPX. Previous studies found that TM3 residues differentially impacted A 1 AR orthosteric antagonist versus agonist binding. Mutation of L88 3.33 A caused a substantial reduction of both agonist and antagonist affinity at the A 1 AR, whereas and V87 3.32 A has been shown to decrease antagonist affinity alone and Q92 3.37 A has been shown to perturb agonist affinity only (Rivkees et al., 1999) . In the main poses after MD simulation, V87 3.32 and L88 3.33 A were predicted to have hydrophobic interactions with both DPCPX and NECA, while Q92 3.37 only interacted with NECA (Site 1) ( Supplemental Fig. 4 ).
This article has not been copyedited and formatted. The final version may differ from this version. Therefore, the key interactions predicted from our molecular modelling are in agreement with previous mutagenesis studies and further support a deeper orthosteric-binding pose for NECA (Site 1) relative to the antagonist, DPCPX. It should be noted, however, that the single identified stable pose of the antagonist, DPCPX, is higher-placed such that it overlaps with both NECA-binding clusters i.e., within the orthosteric agonist pocket (Site 1) and the extracellular vestibule (Site 2) to antagonize agonist access.
ECL2 has also been suggested to facilitate ligand access from the extracellular space into the orthosteric TM binding cavity. For instance, in unbiased long time scale MD simulations, β adrenoceptor orthosteric ligands recognized an intermediate binding site within the extracellular vestibule during the transition from the extracellular space into the TM bundle (Dror et al., 2011) .
Furthermore, the importance of ECL2 flexibility and conformational integrity was highlighted in a study on the M 2 muscarinic acetylcholine receptor, where a reduction in ECL2 flexibility due to the introduction of a disulfide bond between ECL2 and TM7, caused a significant decrease in orthosteric and allosteric ligand affinity . Supporting a role of ECL2 in facilitating ligand entry into the orthosteric site, our docking of NECA in the active-like A 1 AR homology model found 31 of the top 40 poses recognized a common site within the extracellular vestibule. The main pose from the MD simulation performed on NECA docked within this site had hydrogen-bonding interactions between the ligand and E170 ECL2 , E172 ECL2 , K265 ECL3 , S267 ECL3 and T270 7.35 . ECL2 residues located within 3.5 Å of this NECA pose were E170 ECL2 , F171 ECL2 , E172 ECL2 and M177 ECL2 . Two of these residues, F171 ECL2 and E172 ECL2 are also involved in the formation of the orthosteric pocket within the TM bundle. Nonetheless, the existence of the Site 2 binding pocket is supported by ECL2 alanine scanning mutagenesis, which found a significant decrease in NECA affinity at the A 1 AR mutations E170 ECL2 A, E172 ECL2 A and M177 ECL2 A.
Furthermore, alanine mutation of residues predicted from our MD simulations to interact with NECA at this extracellular site, K265 ECL3 and T270 7.35 , caused a significant decease in NECA This article has not been copyedited and formatted. The final version may differ from this version. affinity and/or efficacy. Of note, β 2 -adrenoceptor residues that form key interactions with orthosteric ligands within the extracellular vestibule, Y308 7.35 and F193 ECL2 (Dror et al., 2011), correspond to T270 7.35 and F171 ECL2 identified within our study. Initial recognition within the extracellular vestibule (Site 2) may act as a 'selectivity filter' for GPCRs. The relatively open nature of the extracellular vestibule may lead to Site 2 being more populated by a range of ligands, however only those that form the appropriate metastable poses will eventually transition into Site 1.
In contrast, ligands that do not form these metastable interactions within Site 2 will leave this site and dissociate from the receptor. Collectively, these data add weight to the notion that the ECL2 of numerous class A GPCRs contributes to an extracellular vestibule that can bind small molecules,
including orthosteric agonists as well as allosteric modulators.
Within this study, alanine mutation of a number of residues in the middle of ECL2, which are predicted from molecular modeling to be distinct from the orthosteric site, caused a significant decrease in orthosteric ligand affinity and/or efficacy. This is perhaps unsurprising given the flexible nature of ECL2 and therefore the spectrum of conformations it likely assumes.
Furthermore, ECL2 has not been well defined within A 2A AR crystal structures, with many residues not resolved within this region. However, ECL2 residues suggested from alanine scanning mutagenesis to be involved in orthosteric ligand binding may influence the energetics of the unbound receptor conformations and/or facilitate the transition of ligands from the extracellular space into the orthosteric site. Indeed, we identified a cluster of four residues at the TM4 end of ECL2 that perturbed NECA efficacy in the absence of an effect on affinity, indicating that ECL2 is involved in the stabilization of A 1 AR active states. These findings are in line with previous studies of other family A GPCRs where mutations within ECL2 perturbed orthosteric agonist efficacy (May et al., 2007; Scarselli et al., 2007; Gregory et al., 2010; Wifling et al., 2015) . At a number of GPCRs, including the M 2 muscarinic acetylcholine and glucagon-like peptide-1 receptor, ECL2 differentially influences orthosteric agonist efficacy depending upon the signalling pathway This article has not been copyedited and formatted. The final version may differ from this version. assessed (Gregory et al., 2010; Koole et al., 2012) , and as such is thought to play a key role in the stabilization of different active states that contribute to the phenomenon of biased agonism. In the future, it will be pertinent to explore the influence of these ECL2 residues on the bias profile of A 1 AR agonists.
Informed by our iterative approach that combined site-directed mutagenesis and molecular modeling with rigorous analysis delineating effects of select A 1 AR residues on orthosteric affinity and efficacy, we have demonstrated a key role for ECL2 in A 1 AR agonist and antagonist binding and function. Our analysis indicated that agonist ligand affinity and efficacy determinants could be clearly delineated into two major clusters. In addition to making direct contact with ligands bound to the transmembrane bundle, we propose that ECL2 forms an extracellular vestibule that is recognized by, and facilitates the binding of, orthosteric agonists. It would be of interest to determine the extent to which this vestibule also contributes to the actions of A 1 AR allosteric ligands.
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